Bruker与ANPC合作，以支持与Covid-19威胁作斗争的主要新一线响应

The ANPC team, led by world-renowned phenomics pioneer and academician Professor Jeremy Nicholson, and working with the South Metropolitan Health Service COVID-19 Response Team and the broader Western Australian (WA) healthcare community, has launched a major research and diagnostics project to better understand and predict variation in COVID-19 severity and determine the complex genetic, environmental and lifestyle interactions that influence its pathogenicity in individuals. Later they will engage with clinical trials of novel antiviral agents and when available vaccines in order to predict responder/non-responder outcomes.

目的是在加速的时间范围内提供诊断和预后解决方案。最重要的是，需要迅速评估受感染患者严重程度的风险，以帮助指导和优化临床患者途径。ANPC的研究人员将使用一系列最先进的Avance IVDR核磁共振（NMR）和Timstof Pro，Impact II和Solarix MR质谱法（MS）仪器（MS）仪器（MS）仪器（MS）仪器，以及数据建模方法，以及对血浆和尿液样品的分子，物理和生化特征进行广泛而深层的代谢分析，以创建信息丰富的翻译模型。这些模型将预测疾病严重程度的差异，并有助于了解治疗干预措施的差异反应。

尼科尔森教授说：“在ANPC，我们将100％的资源献给了Covid-19至少一年。这是地球上最大的新兴医疗挑战，在澳大利亚或世界任何地方都没有更好的代谢实验室在出色的临床和医院框架中进行此类调查工作。

“Linked to our genomics team, led by Professor Simon Mallal and Associate Professor Mark Watson, we’re setting out to identify specific biomarkers of the disease to figure out who has it, how we can detect it and stratify patients by severity risk, and assess the real time patient responses to treatments.”

布鲁克公司（Bruker Corporation）总裁兼首席执行官弗兰克·H·劳基恩（Frank H. Laukien）评论说：“我们强烈致力于支持尼科尔森教授及其团队在科学和技术上。默多克大学的综合COVID-19临床研究计划涉及疾病，预后和治疗反应的代谢生物标志物模式。

“In particular, I hope that the team can find evidence-based clinical protocols very soon to reduce mortality in ‘phase 2’ of COVID-19 with its life-threatening lower respiratory tract infections. Medical science needs to determine urgently whether broad spectrum antibiotics and/or immunosuppressants improve survival statistics in ‘phase 2’, when viral pneumonia, potential bacterial pneumonia or ventilator-associated pneumonia (VAP), as well as lung inflammation due to our own immune systems’ cytokine storms, appear to create a very dangerous set of co-morbidities.”

https://www.youtube.com/watch?v=Jki8Bw9cg5Q&feature=emb_title

The project will see the ANPC working hand-in-hand with Professor Merrilee Needham of Murdoch University and Notre Dame University, and Professor Toby Richards of the University of Western Australia, who are bringing together the top doctors and researchers from WA through the Western Australian Health Translation Network (WAHTN) led by Professor Gary Geelhood for the COVID-19 Response Team.

It is anticipated that all new COVID-19 patients will be consented for testing on admission and later for clinical trials, with the ANPC running the samples from those trials and tests, including longitudinal urine and plasma metabolic monitoring.

Commenting on the unique position of the WA-based research team, Professor Richards said: “We are in the second wave and have the opportunity to be prepared for COVID-19. We have built a unique platform in WA to collect patient data and bio samples to enable a thorough understanding of the disease and response to treatment.”

了解感染的途径和生物学后果将使有效的治疗和疫苗能够减轻当前对全球成千上万人的威胁。这项开创性的工作还将为我们做好准备，以应对未来的病毒大流行威胁。

The Australian National Phenome Centre (ANPC), led by Murdoch University, will transform how long and how well people live, not just in Australia, but around the world. The work of the ANPC supports almost every area of bioscience. It reaches across traditional research silos and fosters a new, more collaborative approach to science. Long-term, the ANPC hopes to build ‘global atlases’ of human disease, providing insights into future health risks which everyone on the planet can benefit from. The only facility of its kind in the southern hemisphere, the ANPC brings together all five Western Australian universities and leading health and medical research institutes. It is linked to the International Phenome Centre Network and also has wide applications in agriculture and environmental science. The ANPC positions Perth and WA as a global leader in precision medicine, and enables quantum leaps in predicting, diagnosing and treating disease. It is part of the Health Futures Institute at Murdoch University.

The ANPC is equipped with multiple state-of-the-art nuclear magnetic resonance (NMR) and mass spectrometry (MS) instruments from ANPC strategic alliance partners Bruker BioSpin and Bruker Daltonics. Bruker is a manufacturer of scientific instruments for molecular and materials research, as well as for industrial and applied analysis.

一个人的现象是其独特生物学的动态指纹，这是由于环境和遗传因素之间的复杂相互作用而产生的。现象学是对环境和人的生活方式如何与基因相互作用以影响其健康和疾病风险的研究。代谢表型是对生物组织和液体的分析，以发现分子水平上遗传，环境和生活方式因素的特定相互作用。

Professor Jeremy Nicholson

尼科尔森教授领导了国际代谢表型和系统医学领域的国际知名先驱。他目前担任默多克大学健康期货研究所的职业副校长。尼科尔森教授是一位受到引用的学者，他发表了有关人体系统医学分子方面的800多篇同行评审论文。尼科尔森教授是英国医学科学院的会员，他从伦敦帝国学院来到西澳，在那里他是MRC-NIHR国家现象中心的创始董事，也是先前的外科和癌症主管。他目前是伦敦帝国学院的名誉生物化学教授。

伊莱恩·福尔摩斯教授

Another systems medicine pioneer, Professor Holmes is a Highly Cited Scholar and a Fellow of the UK Academy of Medical Sciences. Professor Holmes also comes to WA from Imperial College London where she was previously Head of the Division of Computational and Systems. She is Professor of Computational Medicine and a Premiers’ Fellow, Australian National Phenome Centre, Murdoch University She also holds a current appointment at Imperial College London as Professor of Chemical Biology.

Dr Ruey-Leng Loo

Premier’s Intermediate Fellow, Senior Lecturer, ANPC, Murdoch University.

Professor Toby Richards

迈克尔·劳伦斯·布朗（Michael Lawrence Brown）手术主席UWA，名誉教授临床试验方法学院学院伦敦学院，导演Covid Research Response。

梅里利·尼德姆（Merrilee Needham）教授

Senior Consultant, Director of Research, Fiona Stanley Hospital, Murdoch University & University of Notre Dame Australia.